english.prescrire.org > Spotlight > 100 most recent > Gefapixant (Lyfnua°) in refractory or unexplained chronic cough

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Gefapixant (Lyfnua°) in refractory or unexplained chronic cough

 Marketing Authorisations  Gefapixant, an antagonist of the purinergic receptors P2X3 and P2X2/3, has been authorised in the European Union for use in adults with refractory or unexplained chronic cough. Does gefapixant alleviate the symptoms or complications of chronic cough? Does it stop patients from coughing or reduce cough frequency? And what are its adverse effects?
Full article available for download by subscribers

EDITORS' OPINION
Anticipate

When a new drug is authorised, there are always many unknowns concerning its adverse effects. Clinical trials examine only a tiny fraction of clinical situations, the patients enrolled represent only a tiny fraction of human diversity, and the duration of evaluation is often very short. Nevertheless, some of the adverse effects of a new drug are foreseeable from its pharmacological class, its chemical structure, and its presumed mechanism of action, and from animal data and observations from the initial clinical trials...

Full text available for download by subscribers

 ©Prescrire 1 November 2025

Source: "Gefapixant (Lyfnua°) in refractory or unexplained chronic cough" Prescrire Int 2025; 34 (275): 257-260. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information